IRadimed Expects Q3 FY23 Revenue Of $16.1M-$16.3M Vs. Consensus Of $15.6M; Sees Adjusted EPS OF $0.36-$0.38 Vs. Consensus Of $0.33
Portfolio Pulse from Benzinga Newsdesk
IRadimed has projected its Q3 FY23 revenue to be between $16.1M and $16.3M, surpassing the consensus estimate of $15.6M. The company also anticipates its adjusted EPS to be between $0.36 and $0.38, higher than the consensus estimate of $0.33.
August 04, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IRadimed's higher than expected Q3 FY23 revenue and adjusted EPS projections may positively impact its stock price.
IRadimed's projected Q3 FY23 revenue and adjusted EPS exceed consensus estimates, which is typically a positive signal to investors and can lead to an increase in the stock price. The company's strong financial performance indicates its ability to generate higher profits, which is a key driver of stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100